Generic Pharmaceuticals, APIs & Healthcare Products — India to the EU
Facilitating compliant trade in generic drugs, active pharmaceutical ingredients, nutraceuticals, and medical devices between Indian manufacturers and European buyers.
India is the world's largest producer of generic pharmaceuticals by volume, supplying over 20% of global generics. Yet accessing EUGMP-compliant manufacturers, navigating Article 23 dossier submissions, and managing the complex documentation chain deters many European buyers. We act as the informed intermediary: identifying WHO-GMP or EUGMP-certified manufacturers, facilitating initial commercial discussions, and coordinating with regulatory consultants to keep supply chains compliant — on a commission-only basis.
India–EU FTA Relevance
The India–EU FTA is expected to include pharmaceutical market access provisions, potentially streamlining mutual recognition of GMP inspections and reducing duplicative regulatory burden. This would be a significant structural enabler for Indian generic exports to the EU — and may accelerate EU investment into Indian contract manufacturing infrastructure.
We charge 3–7% of invoice value for successfully closed commercial introductions. Given the regulatory complexity of pharmaceutical deals, upfront consultancy fees may apply for mandate scoping (€500–2,000 one-time), credited against the success commission on first deal close.
All commissions confirmed in writing via NCNDA + Commission Agency Agreement before any introduction. Five-year non-circumvention protection. Payment typically net 10 business days from trigger event.
Subject-matter expertise + global network + documented deal process. The only intermediary model that works across borders.
01
Manufacturer Identification
We identify WHO-GMP or EUGMP-certified Indian pharmaceutical manufacturers for specific molecules, dosage forms, or device categories — providing regulatory status summaries and capacity data.
02
Commercial Introduction & Negotiation
We facilitate introductions between Indian manufacturers and European marketing authorisation holders (MAHs), distributors, or hospital buying groups, and participate in commercial term negotiations.
03
API Sourcing
Active pharmaceutical ingredient sourcing from DMF-filed Indian manufacturers for European formulators. We verify DMF status, CEP (Certificate of Suitability) availability, and impurity profiles.
04
Nutraceuticals & Herbal Extracts
India's botanical extract and nutraceutical industry is globally competitive. We source standardised herbal extracts, vitamins, minerals, and functional food ingredients for European supplement brands.
05
Medical Device Coordination
We identify Indian ISO 13485-certified manufacturers for Class I and Class IIa medical devices — surgical instruments, disposables, diagnostics — seeking EU market entry partnerships.
06
Regulatory Liaison
We work alongside licensed EU regulatory consultants for dossier strategy, technical file preparation, and GMP gap analysis — complementing our commercial facilitation role.
Full Bilateral Scope
Everything we can facilitate
A comprehensive scope of facilitation activity within this vertical — from first introduction through to repeat order management and multi-year supply agreements.
Medical devices: Class I–IIa, surgical instruments, disposables
Diagnostics: IVD kits, point-of-care devices
Veterinary pharmaceuticals: generics and biologics
Contract manufacturing (see CMO vertical 15)
Bilateral Flow
India ↔ World
🇮🇳 India Provides / Sources
🌍 Global Market Provides / Seeks
Indian WHO-GMP/EUGMP manufacturers
EU MAHs, distributors, hospital groups, pharmacy chains
European innovative pharma IP holders
Indian generic manufacturers seeking licensing or technology transfer
Distribution Channel Development
We actively develop distribution channels via targeted prospecting with product samples, pilot shipments, and trial orders. Every new buyer relationship begins with a qualification call, followed by a documented sample or pilot order to prove commercial viability before any long-term commitment is made. This is the most effective route to sustainable bilateral volume.
Sector Intelligence
Historical Trends · Future Outlook · FTA Impact
Subject-matter intelligence underpinning our advisory and deal origination in this vertical. Updated annually by Vinod Kumar Jain (India-side) and Amit Jain (EU-side).
Historical Context
How This Sector Evolved
◆India emerged as the "pharmacy of the world" through the 1990s–2000s, with CIPLA, Dr. Reddy's, Sun Pharma, and hundreds of SME manufacturers building WHO-GMP compliant production for regulated EU/US markets.
◆The global HIV/AIDS crisis (early 2000s) established India's moral authority in generic medicine supply — CIPLA's pricing of ARV drugs for African markets became a landmark moment in pharmaceutical trade history.
◆EU tightened GMP inspection requirements from 2012 onwards (Falsified Medicines Directive, GDP regulations) — increasing compliance costs for Indian exporters but rewarding those who invested in EUGMP upgrades.
◆India's API (Active Pharmaceutical Ingredient) industry built world-class capability in synthesis routes for key molecules — making European formulators dependent on Indian APIs even for products that are "EU-made" finished dose.
◆COVID-19 (2020–2022) made the world aware of API supply chain concentration in India and China — accelerating EU discussions about pharma supply chain resilience and the strategic importance of India as a dependable supply partner.
Future Outlook 2025–2030
Where This Sector Is Heading
▶India–EU FTA services provisions and potential GMP mutual recognition could eliminate costly parallel inspection requirements — reducing the cost of Indian plant qualification for EU supply by €100k–500k per facility.
▶Biosimilars: India's biosimilar manufacturers (Biocon, Dr. Reddy's, Intas) are building EUGMP-compliant biologics capability — the next wave of Indian pharma exports targeting the EU patent cliff in monoclonal antibodies.
▶Nutraceuticals and Ayurveda: EU consumer health supplement market growing at 7% CAGR — Indian standardised botanical extracts, adaptogen formulations, and Ayurvedic OTC products represent significant EU market entry opportunity.
▶Contract manufacturing (CMO) consolidation: EU pharma brands facing European CMO capacity constraints and cost inflation increasingly evaluating Indian EUGMP CMOs as primary manufacturing sites rather than backup.
▶Digital health and diagnostics: Indian IVD (In Vitro Diagnostic) manufacturers scaling IVDR-compliant production for EU market entry — a category that barely existed in India five years ago.
📈
India–EU FTA Impact
Medium Impact
EU tariffs on Indian pharma are already low (0–5%) so the tariff reduction dimension is modest. The significantly higher FTA impact comes from two non-tariff provisions: (1) potential GMP mutual recognition, which would reduce the cost and time of Indian plant qualification for EU supply — making Indian CMOs commercially viable for many more EU brands; and (2) IP chapter provisions that, if balanced correctly, could increase European IP holders' confidence in licensing technology to Indian manufacturers. The services chapter (Mode 4) also opens potential for Indian regulatory affairs professionals to support EU pharma operations directly.
Each niche within this vertical has distinct buyer profiles, certification requirements, commission structures, and FTA dynamics. Global Nexus operates across all of the following sub-categories.
API (Active Pharmaceutical Ingredients)
Indian APIs to EU manufacturing plants. EUGMP Annex 18. Fastest EU revenue path.
3–5% pa
Generic Formulations (Finished)
EU market authorisation pathway. WHO-GMP + EUGMP + QP required.
4–7% pa
Nutraceuticals & Supplements
EU food supplement regulation (lighter than pharma). Fastest EU market entry.
4–6% pa
OTC / Consumer Health
Cosmetics, vitamins, herbal. EU Cosmetics Regulation or food supplement law.
4–7%
Contract Manufacturing (CMO)
EU brand manufacturers in India (WHO-GMP facility). Annual contract basis.
3–6% pa
Biosimilars (emerging)
Indian biosimilar producers targeting EU EMA pathway. Long lead time, high value.
5–8% pa
Risk Management
Key Risks & How We Mitigate Them
Every trade mandate carries risk. The following are the most common risks in this vertical — and exactly how Global Nexus structures deals to address each one.
⚠ Risk
GMP Non-Compliance
Indian manufacturer produces to CDSCO (Indian) GMP but EU authority inspection finds gaps in EU GMP compliance — supply suspended and EU launch delayed.
✓ Mitigation
Global Nexus pre-qualifies manufacturers with BOTH CDSCO WHO-GMP certification AND evidence of EU GMP inspection or readiness assessment. The India-EU FTA MRA framework (in negotiation) aims to reduce dual inspection burden.
⚠ Risk
Dossier Rejection by EMA/National CA
Marketing Authorisation Application (MAA) rejected due to documentation gaps — bioequivalence data, stability data, or impurity profiling.
✓ Mitigation
Global Nexus works with specialist regulatory affairs consultants (EU-registered) who conduct pre-submission gap analysis before MAA filing. Cost of pre-submission review: 2-5% of total dossier cost — versus cost of a rejection (18-36 month delay and full resubmission cost).
⚠ Risk
Qualified Person Liability
EU Qualified Person certifies a batch from Indian manufacturer — subsequent quality failure creates personal liability for the QP and supply disruption.
✓ Mitigation
EU QP arrangements structured with clear technical agreements (QA) between the QP service provider and the Indian manufacturer. QP audits Indian site before batch release mandate commences.
Practitioner Intelligence
Tips & Insights from the Field
Drawn from Vinod Kumar Jain's 30+ years of India-side manufacturing relationships and Amit Jain's EU-side buyer and regulatory experience. These are the insights that differentiate deals that close from those that don't.
Approach EU nutraceutical brands, not pharma companies, first
EU nutraceutical and food supplement brands operate under lighter regulation than licensed pharmaceuticals — no EMA approval required, no QP needed. The WHO-GMP certified Indian manufacturer can supply EU nutraceutical brands immediately, building the relationship that can expand to licensed pharma as regulatory alignment progresses.
💡
The FTA MRA is a multi-year project — plan for it now
The India-EU FTA Mutual Recognition Agreement (MRA) for GMP inspections will reduce the cost of EU market entry for Indian manufacturers — but implementation will take years after FTA entry into force. Manufacturers who complete EU GMP readiness now will benefit from Day One of MRA implementation.
💡
API supply is the fastest path to EU revenue
EU pharma manufacturers buy Indian APIs at scale — often without requiring the Indian producer to have a marketing authorisation in the EU themselves. API supply to EU manufacturers is governed by the API EUGMP Annex 18 — achievable within 12-18 months of focused preparation.
Ready to discuss a deal in this sector?
Porto, Portugal · +91 98881 47147 Panchkula, India · +91 98881 47147
Answers drawn from twenty-plus years of bilateral trade and advisory experience across this vertical.
We do not ourselves submit dossiers, but we work alongside licensed EU-based regulatory consultants who do. We coordinate commercially; they handle the regulatory paperwork.
We only introduce manufacturers with current WHO-GMP certification. For EU-specific supply, we focus on EUGMP-inspected facilities. We verify certification status before any introduction.
We can attempt to locate Indian API manufacturers for speciality molecules, but success depends on whether a DMF-filed Indian producer exists. We will advise you honestly if the molecule is not feasibly sourced from India.
Regulatory compliance for food supplements varies by EU member state. We advise buyers to conduct their own compliance review, and can connect them with EU food law specialists.
Longer than other verticals. Manufacturer identification and technical exchange: 4–8 weeks. Commercial negotiation: 4–12 weeks. Regulatory alignment: 3–18 months depending on registration pathway. We set realistic expectations from day one.
Have a question not answered here? Write to us directly — we respond to every enquiry personally within one working day.